NY-IWBI
8.6.2020 17:03:03 CEST | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today the launch of the WELL Health-Safety Rating for all building and facility types, an evidence-based, third-party verified rating focusing on operational policies, maintenance protocols and design strategies to address a post COVID-19 environment. The WELL Health-Safety Rating is one of the earliest outcomes of IWBI’s Task Force on COVID-19 , a group of nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals, which was established in late March to help guide IWBI’s response to the pandemic.
The WELL Health-Safety Rating provides a centralized source and governing body to validate efforts made by owners and operators. It leverages insights drawn from the IWBI COVID-19 Task Force, in addition to guidance on the spread of COVID-19 and other respiratory infections developed by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Department of Health and Human Services pursuant to the Occupational Safety and Health Act (OSHA), the National Institutes of Health (NIH), and leading academic and research institutions, as well as core principles already established by IWBI’s WELL Building Standard. Participation in the program requires submission of policies, protocols and strategies for third-party document review and annual verification.
“The WELL Health-Safety Rating is a sign of confidence that measures have been enacted to help support the health and safety of people entering spaces of all kinds, and that those measures have been mapped to scientific evidence and verified through a third-party review process,” said Rick Fedrizzi, chairman & CEO of IWBI. “By drawing on the proven strategies in WELL, we’re working from the best science available and that’s more important than it’s ever been.”
The WELL Health-Safety Rating will accept registrations in June from all types of buildings and facility typologies, including offices, restaurants, hotels, retail establishments, manufacturing plants, warehouses, sports stadiums, arenas, theaters and other entertainment venues, schools, multi-family housing, and many others. Current WELL-registered projects and WELL Portfolio participants can earn the WELL Health-Safety Rating as part of their already established certification efforts.
“Our buildings and the people who tend them are our first line of defense for keeping us safe and healthy,” said Rachel Gutter, president of IWBI, “and the current pandemic has confirmed that health is a material economic consideration of the first order. These two simple truths stand at the nexus of our work to date and will, along with the hard evidence that is mounting, inform all our decisions about the critical need for better buildings, more vibrant communities and stronger organizations going forward.”
The WELL Health-Safety Rating is the first of many anticipated outcomes informed by the work of the IWBI COVID-19 Task Force that will be introduced in the coming months. Members of the Task Force include 17th Surgeon General of the United States Dr. Richard Carmona, former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, Harvard School of Public Health’s Joseph Allen, and environmental scientist Allen Hershkowitz Ph.D., among others.
“The Task Force has received overwhelming support and input from all over the world,” said Dr. Richard Carmona, 17th Surgeon General of the United States. “People are learning that buildings themselves can be powerful vehicles for protecting and improving public health. All of us individually have a responsibility to the collective whole to use every tool, including our buildings and our sense of community, to keep ourselves and those we care about safe.”
“The impacts of the virus have been many, but not the least is the anxiety of uncertainty about where people feel safe,” said Despina Katsikakis, Head of Occupier Business Performance at Cushman Wakefield and member of IWBI’s COVID-19 Task Force. “Achieving this new WELL Health-Safety Rating is a great way to increase confidence that evidence-based steps to do the right thing have been taken to keep health front and center as the economy reopens.”
Recently, IWBI released an interim Strategies from the WELL Building Standard to Support in the Fight Against COVID-19, another key outcome of the Task Force. Grounded in the foundation of WELL, these evidence-based strategies provide an actionable framework for organizations and communities as they advance a safer and healthier future. IWBI is expanding these strategies into Guidelines for Preparedness and Prevention, Resilience and Recovery in relation to COVID-19 and other respiratory infections. The Guidelines will provide insight into how the current strategies have evolved, as well as indicate areas where further work is required.
Since its inception, IWBI has been driving forward the convergence of building science and health science. Registrations under the WELL Building Standard, the premier standard for healthy real estate, have already surpassed 550 million square feet across 62 countries. The WELL Building movement has been further amplified by over 11,000 WELL Accredited Professionals (APs) and registrants across the globe.
Gutter noted that upon achieving the designation, IWBI will issue the project a WELL Health-Safety Rating seal. Register interest in the WELL Health-Safety Rating here .
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness for everyone, everywhere. For more information about IWBI and WELL, visit us here .
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005495/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
